506U78 in Treating Patients With Refractory Hematologic Cancer - Related Studies

506U78 in Treating Patients With Refractory Hematologic Cancer

This study is ongoing, but not recruiting participants.

Study NCT00002970. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Lymphoma

2	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

3	Interventions listed in this trial
		cytarabine
		methotrexate
		nelarabine
		therapeutic hydrocortisone

4	Additional drug interventions recognized in this trial
		Cortisol succinate
		Hydrocortisone
		Hydrocortisone acetate

5	More general drug interventions related to this trial
		Abortifacient Agents
		Abortifacient Agents, Nonsteroidal
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antirheumatic Agents
		Antiviral Agents
		Dermatologic Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Reproductive Control Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Pediatric Oncology Group
		National Cancer Institute (NCI)
		Children's Cancer Group